Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

Rituximab 8Vemurafenib 4Cyclophosphamide 4Cladribine 4Specimen Handling 3Diphenhydramine 3Biopsy 3Acetaminophen 3obinutuzumab 2ibrutinib 2fludarabine phosphate 2fludarabine 2binimetinib 2Dexamethasone 2Calcium Dobesilate 2CT-P10 2Bendamustine Hydrochloride 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1immunotoxin HA22 1encorafenib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brexucabtagene autoleucel 1auricularum 1acalabrutinib 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Histamine Antagonists × 1 year × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡